This is suggested not only by the fact of poorer clinical outcomes for patients with LRP-expressing tumours, but also by the observed correlation between LRP and well-known factors conferring bad prognosis such as high β-hCG levels and visceral metastatic disease. The gene discussed is MVP; the disease is neoplasm.